Working… Menu
Trial record 94 of 543 for:    Celecoxib

Effects of Celecoxib After Percutaneous Coronary Intervention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00292721
Recruitment Status : Completed
First Posted : February 16, 2006
Last Update Posted : July 21, 2011
Information provided by:
Seoul National University Hospital

Brief Summary:
Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Condition or disease Intervention/treatment Phase
Coronary Arteriosclerosis Drug: Celecoxib Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial
Study Start Date : August 2004
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Celecoxib

Arm Intervention/treatment
No Intervention: Control
Active Comparator: Celecoxib Drug: Celecoxib
celecoxib: loading and maintenance for 6 months

Primary Outcome Measures :
  1. Late luminal loss at 6 months [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography

Exclusion Criteria:

  • Acute ST elevation MI
  • Left main disease
  • Contraindications to aspirin, clopidogrel or celecoxib
  • Severe congestive heart failure
  • Expected survival < 2 years
  • Hepatic dysfunction
  • Currently taking NSAIDs or any COX-2 inhibitor
  • Renal dysfunction
  • Use of warfarin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00292721

Layout table for location information
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Layout table for investigator information
Principal Investigator: Bon-Kwon Koo, MD, PhD Seoul National University Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Seoul national university hostpial, Seoul National University Hospital Identifier: NCT00292721     History of Changes
Other Study ID Numbers: 134-가-37
First Posted: February 16, 2006    Key Record Dates
Last Update Posted: July 21, 2011
Last Verified: July 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action